Recombinant Endopeptidase Production Method
Summary
NEMYSIS LIMITED filed US Patent Application US20260109962A1 on July 2, 2025, covering a method for manufacturing an enzyme preparation comprising recombinant Actinoallomurus endopeptidase with glutenase activity at high yields suitable for human use. The application also discloses a recombinant expression vector, S. lividans host cell comprising said vector, the resulting enzyme preparation, formulations thereof, and clinical uses. Published April 23, 2026.
“The present invention is directed to a method for manufacturing an enzyme preparation, comprising at least one recombinant Actinoallomurus endopeptidase with glutenase activity, at high yields and suitable for human use.”
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 236 changes logged to date.
What changed
NEMYSIS LIMITED has filed a patent application (US20260109962A1) disclosing a method for producing recombinant Actinoallomurus endopeptidase with glutenase activity at high yields suitable for human use. The application covers the recombinant expression vector, S. lividans host cell containing said vector, the enzyme preparation obtained thereby, formulations, and clinical uses thereof.
For companies in the enzyme manufacturing, pharmaceutical, or food science sectors, this application signals competitive activity in the glutenase enzyme space. Parties developing similar enzyme products or considering licensing arrangements should review the published claims when available. The patent application does not create compliance obligations but represents prior art for subsequent filings in this technical area.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHOD FOR THE PRODUCTION OF AN ENZYMATIC COMPOSITION COMPRISING A RECOMBINANT ENDOPEPTIDASE
Application US20260109962A1 Kind: A1 Apr 23, 2026
Assignee
NEMYSIS LIMITED
Inventors
Anna Taravella, Giacomo Enrico Carenzi, Alessandro Sigurta', Linda Cavaletti
Abstract
The present invention is directed to a method for manufacturing an enzyme preparation, comprising at least one recombinant Actinoallomurus endopeptidase with glutenase activity, at high yields and suitable for human use. The invention is further directed to a recombinant expression vector for expressing the recombinant endopeptidase(s) of interest, and to a S. lividans host cell comprising said vector. Moreover, the present invention is directed the enzyme preparation obtained by said method, to formulations of the same and to clinical uses thereof.
CPC Classifications
C12N 9/52 A21D 8/042 A23L 29/06 A23L 33/10 A23L 33/40 A61K 38/48 C12N 1/20 C12N 15/76 C12Y 304/21026 A23V 2002/00 C12N 2800/101
Filing Date
2025-07-02
Application No.
19257513
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.